Anti-inflammatory therapies to treat sepsis and septic shock
- 1 July 1997
- journal article
- editorial
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 25 (7), 1095-1100
- https://doi.org/10.1097/00003246-199707000-00001
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Confirmatory interleukin-1 receptor antagonist trial in severe sepsisCritical Care Medicine, 1997
- Treatment of Severe Systemic Inflammatory Response Syndrome and Sepsis With a Novel Bradykinin Antagonist, Deltibant (CP-0127)Results of a Randomized, Double-blind, Placebo-Controlled TrialPublished by American Medical Association (AMA) ,1997
- Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shockCritical Care Medicine, 1996
- Pilot clinical trial of an anti-TNFα monoclonal antibody for the treatment of septic shockClinical Intensive Care, 1995
- Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trialCritical Care Medicine, 1994
- Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis SyndromeJAMA, 1994
- Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of PathogenesisAnnals of Internal Medicine, 1994
- Clinical Safety, Tolerability, and Pharmacokinetics of Murine Monoclonal Antibody to Human Tumor Necrosis Factor-The Journal of Infectious Diseases, 1994
- Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsisCritical Care Medicine, 1993
- Monoclonal antibody to TN F in severe septic shockThe Lancet, 1990